Competing interests
AML, T-ALL, Neomorph
ONCOLOGY, T-ALL, AML, EMD
G.C.I. received consultancy or advisory role fees from Novartis, Kura Oncology and NuProbe and received research funding from Celgene, Novartis, Kura Oncology, Syndax Pharmaceuticals, Merck, Cullinan Oncology and NuProbe. I.A. received consultancy or advisory role fees from Amgen, Pfizer, Jazz, AbbVie and Agios, research funding from AbbVie and Macrogenics and honoraria from Amgen, Pfizer, Jazz, AbbVie and Agios. J.D.P. has a consultancy role with Incyte and RiverVest Venture Partners, has served as a board member or advisory committee member for RiverVest Venture Partners, Magenta, hC Bioscience, Inc. and WUGEN, has received research funding from NeoImmune Tech, Macrogenics, Incyte, Bioline Rx and WUGEN and holds patents or pending patents for UCART7 for treatment of T-ALL, VLA-4 inhibitors for stem cell mobilization and NT-I7 for CART expansion. R.S. has served on the steering committee of AbbVie and advisory boards of AbbVie, AvenCell, CTI Pharma, Kura One, Genentech, Actinium, Arog, BMS, Boston Pharmaceuticals, GSK, Janssen, Jazz, Novartis, Syros, Takeda, Elevate Bio, Syndax Pharmaceuticals, Gemoab, BerGenBio, Foghorn Tera, Aprea, Innate, Actinium and OncoNova; served as DSMB for Aptevo, Epizyme, Takeda and Syntrix/ACI Clinical; on the focus group of BerGenBio; and on AML Expert Council of GSK and Grand Rounds of Jazz Pharmaceuticals. M.A. has served on the advisory boards of Kite Pharma and Syndax Pharmaceuticals. M.J.T. has a consulting or advisory role with AbbVie and CVS, has an expert testimony role with Apotex and received research funding from AbbVie, Gilead Sciences, Janssen, Merck, Pharmacyclics, Syndax Pharmaceuticals, TG Therapeutics and Tolero. M.R.P. served in a leadership role with ION Pharma; received honoraria from Pfizer, Pharmacyclics, Bayer, Janssen Oncology, Genentech and Adaptive Biotechnologies; has a consulting or advisory role with Pharmacyclics/Janssen and Pfizer/EMD Serono; served on the Speakers’ Bureau of Exelixis, Genentech/Roche, Taiho Pharmaceutical and Celgene; and received research funding from Acerta Pharma, ADC Therapeutics, Agenus, Aileron Therapeutics, AstraZeneca, BioNTech AG, Boehringer Ingelheim, Celgene, Checkpoint Therapeutics, CicloMed, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo, Lilly, EMD Serono, Evelo Therapeutics, FORMA Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Janssen, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics, Pfizer, Placon, Portola Pharmaceuticals, Prelude Therapeutics, Ribon Therapeutics, Seven and Eight Biopharmaceuticals, Syndax Pharmaceuticals, Taiho Pharmaceutical, Takeda, Tesaro, TopAlliance BioSciences, Inc., Vigeo, ORIC, Artios, IgM Biosciences, Puretech, BioTheryX, Black Diamond Therapeutics, IgM Biosciences, NGM Biopharmaceuticals, Nurix, PureTech, Relay Therapeutics, Samumed, Silicon Therapeutics, TeneoBio, Treadwell Therapeutics, Zymeworks, Olema, Adagene, Astellas, NGM, Accutar Biotech, TeneoBio, Novartis, Compugen, Black Diamond Therapeutics, MabSpace Biosciences, Immunogen and Blueprint Pharmaceuticals. D.S.D. has a consulting or advisory role with Tempus, Inc. S. Shenoy has a consulting or advisory role with Artio, BMS and Takaeda. H.K. received honoraria/advisory board/consulting fees from AbbVie, Amgen, Amphista, Ascentage, Astellas, Biologix, Curis, Ipsen Biopharmaceuticals, KAHR Medical, Labcorp, Novartis, Pfizer, Shenzhen Target Rx, Stemline and Takeda; and received research funding from AbbVie, Amgen, Ascentage, BMS, Daiichi Sankyo, Immunogen, Jazz, and Novartis. S.A.A. received stock or other ownership from Neomorph, Inc., C4 Therapeutics, Cyteir Therapeutics, Accent Therapeutics and Mana Therapeutics; has a consulting or advisory role with Neomorph, Inc., C4 Therapeutics, Cyteir Therapeutics, Accent Therapeutics, Mana Therapeutics and Twentyeight-Seven Therapeutics; received research funding from Syndax Pharmaceuticals and Janssen; and holds patents, royalties and other intellectual property for MENIN inhibition in NPM1 AML: WO/2017/132398A1. G.R. is a former employee of Syndax Pharmaceuticals and a current employee of Boston Pharmaceuticals. R.G.B. is an employee of Syndax Pharmaceuticals and has stock or other ownership at Syndax Pharmaceuticals. M.L.M., P.O. and G.M.M. are employees of Syndax Pharmaceuticals. M.L.M. has a consulting or advisory role at Nuvalent, holds patents, royalties and other intellectual property at Syndax Pharmaceuticals and Nuvalent and has stock or other ownership at Syndax Pharmaceuticals and Johnson & Johnson. P.O. has a consulting or advisory role at Patrys and Twentyeight-Seven Therapeutics, holds patents, royalties and other intellectual property at Syndax Pharmaceuticals and has stock or other ownership at Syndax Pharmaceuticals. G.M.M. has a consulting or advisory role at Syndax Pharmaceuticals, holds patents, royalties and other intellectual property at Syndax Pharmaceuticals and has stock or other ownership at Syndax Pharmaceuticals. Y.G. is an employee of Syndax Pharmaceuticals and has stock or other ownership at Syndax Pharmaceuticals and AstraZeneca. S. Smith has a consultancy or advisory role with Syndax Pharmaceuticals. E.M.S. has a consulting or advisory role with Gilead, CTI Biopharma, Epizyme, AbbVie, Pinotbio, Neoleukin Genesis, Genentech, Jazz, Novartis, Celgene, Calithera, Takeda, Janssen, BMS, Kronos, Kura, Auron, Syndax Pharmaceuticals, Servier, Agios and Remix and received research funding from Biotheryx, Agios, Servier, Eisai, BMS, Bayer, Syndax, Syros and Loxo. B.C., F.P., J.A.P., N.S. and V.K. declare no competing interests.